



LOYOLA
UNIVERSITY
HEALTH SYSTEM

[Some] Adverse Effects of Blood Transfusion

Mehrdad Payandeh ,MD

Kermanshah university of medical science

Immam reza – HSCT center

*Kermanshah blood transfusion conference -
4/feb/2019*

Blood Transfusion is *“Unavoidably Unsafe”*

- High volume
- High cost
- High Risk
- Problem prone



The Risk Side of the Transfusion Equation

- Blood transfusions are the *most common procedure* performed on inpatients in the US.
- Over **21 million** blood components are transfused annually in the US to more than 5 million patients
- Blood transfusions remain the #1 most common *allogeneic tissue transplant* in medicine
- Blood transfusions expose patients to allogeneic antigens much more commonly than the sum of all other tissues and organs transplanted worldwide.

The Risk Side of the Transfusion Equation

- **Infectious disease risks have been vastly reduced over the last 35 years**
 - The viral risks remain “***non-zero***”
 - Bacteria are the *most common* pathogens
 - Constant concerns for *emerging* pathogens
- **Acute adverse effects remain common**
 - *Irreducible* human errors
 - *Irreducible* immunologic risks due to use of allogeneic tissue donors

There are 35 Blood Group Systems & ~ 350 *authenticated Blood Group Antigens*




HLA Antigens – Expressed on WBC's - are

- *THE* Tissue-Typing Antigens
- Are the most polymorphic in man
- Basis of Immune-mediated platelet refractoriness

HLA class I and class II antigens

- Monomer with non-covalently associated subunit (β_2m)
- Presents antigenic peptides to CD8+ T cells
- Expressed by all nucleated cells



- Heterodimer
- Presents antigenic peptides to CD4+ T cells
- Restricted expression on antigen presenting cells (dendritic cells, B cells, macrophages)
- Inducible on other cells (endothelium and epithelium)

Platelet-Specific Alloantigens

- 24 platelet-specific alloantigens defined by immune anti-sera
- 16 are grouped into 8 bi-allelic systems
- The alleles differ by a SNP
- The molecular basis of 22 of 24 have been resolved
- **Platelet-specific antibodies are the pathophysiological basis of**
 - Posttransfusion purpura (PTP)
 - Neonatal alloimmune thrombocytopenia (NAIT)

Platelet-Specific Alloantigen *Families*: “Human Platelet Antigens” [HPA’s]

Antigen Family, Allelic Pairs	Epitopes on Specific Membrane Glycoproteins
HPA-1a/1b	GP IIb/IIIa
HPA-2a/2b	GP-Ib-IX
HPA-3a/3b	GP IIb/IIIa
HPA-4a/4b	GP IIb/IIIa
HPA-5a/5b	GP IIb/IIIa
HPA-6a/6b	GP IIb/IIIa
HPA-9a/9b	GP IIb/IIIa
HPA-15a/15b	CD 109



RESIDUAL INFECTIOUS DISEASE RISKS in TRANSFUSION

Disease Transmitted by Blood	Estimated Frequency per Unit
Hepatitis B virus	1 : 843,000 – 1,280,00
Hepatitis C virus	1 : 1,149,000
HIV- 1 / 2	1 : 1,470,00
HTLV – I / II	< 1 : ~ 3,000,000
WNV	<< 1 : ~ 4,000,000
Bacterial contamination (platelets)	1 : ~ 2000 – 3000 platelet transfusions



Next *Diseases of Concern* for Testing in the Blood Supply

- Arboviruses
 - **Zika**, Dengue, Chikungunya
- *Babesia* species
- Parvovirus B19
- Human v-CJD


Emerging Infectious Diseases and their potential threat to transfusion safety,
Transfusion 2009;49, 1S-29S.

Critical & Fundamental Process Defects

- Blood transfusion is “*unavoidably unsafe*”
- Transfusions = allogeneic tissue transplants
- The complex series of processes to deliver transfusions are performed by imperfect humans
- Process control is often lacking



Transfusion Therapy is a Set of Processes, not just *a Product* or a *Lab Result*



Entire process: *Safe Blood Transfusion*





Systematic Review of RBC Transfusion in the Critically Ill

- 45 studies with a median of 687 patients per study
- Outcome measures, attributed to “*immunomodulation*”
 - Mortality
 - Infection
 - MOF Syndrome
 - ARDS
- **Risks of RBC transfusion outweighed benefits in 42 of 45 studies!!**



Association of Transfusion & Risk of Death




Figure 2. Association between blood transfusion and the risk of death (odds ratio [OR] and 95% confidence interval [CI]). ACS, abdominal compartment syndrome; ICU, intensive care unit.

Transfusion Reactions



- Acute (intravascular) hemolytic reaction
- Delayed (extravascular) hemolytic reaction
- Febrile non-hemolytic reaction
- Allergic (urticarial) reaction
- Bacterial contamination
- Transfusion-related acute lung injury
- Transfusion-associated circulatory overload
- Post-transfusion purpura
- Graft-vs.-host disease



Acute Adverse Effects

- **Immune-Mediated**

- **Acute hemolytic TR's**
- **Fever without hemolysis: FNHTR's**
- **Simple *allergic* reactions**
- **TRALI**
- **Anaphylactoid / anaphylactic reactions**

Acute Adverse Effects

- **Nonimmunologic**
 - **Transfusional hypervolemia**
(circulatory overload), *aka TACO*
 - **Bacterial septic reaction**
 - **Isolated Hypotensive TR's**
 - **Citrate toxicity**
 - **Nonimmune hemolysis (often asymptomatic)**

Acute Transfusion Reactions by Systemic Manifestations

- **Fever and/or chills** (including rigors), no hemolysis
 - R/o acute, immune-mediated hemolysis
 - Work-up required by laboratory Standards
 - **FNHTRs**
 - Bacterial contamination
- **Allergic (Type I hypersensitivity reactions)**
 - Mucocutaneous (pruritus / urticaria) vs. more generalized, involving other organ systems
- **Respiratory Distress**
 - **TACO**
 - **TRALI**
 - May be part of anaphylactoid or anaphylaxis
- **Isolated Hypotensive TR's**
(without cardiovascular collapse)

Estimated Frequencies of Some Adverse Effects of Transfusion




TYPE of Reaction	Reported Frequency
TACO	1 : 68 to 1 : 356 (ICU patients) [Mortality 1 to 3%]
TRALI	1 : 1200 to 1 : 190,000 [Leading reported cause of transfusion-related mortality]
WBC alloimmunization	1 : 20 to 1 : 100
FNHTR's	1 : 100 – 200
Cutaneous allergic	1 : 100 – 300
Delayed serologic	1 : 1500
Delayed hemolytic	1 : 4000
Anaphylactoid	1 : 20,000
Acute hemolysis	1 : 6,000 – 33,000
Anaphylactic	1 : 20,00 to 1 : 50,000
Hypotensive TR's	1 : 18,500




Preventing Acute Hemolysis due to Pre-formed IgM, as seen in ABO-incompatibility

- All steps in **specimen** & **patient** identification are aimed at prevention!
- All pretransfusion testing is done to prevent acute intravascular hemolysis
 - Blood typing & confirmation
 - Antibody screening
 - Crossmatching




Acute Complement-Mediated, Immediate Hemolysis



**The Direct Antiglobulin Test
will be positive**

Acute Intravascular Hemolytic Transfusion Reaction

**IMMEDIATE
HEMOLYTIC
REACTION**




SYMPTOMS

- FEVER • CONSTRICTION OF CHEST
- PAIN IN LUMBAR REGION


SIGNS

- FEVER • HYPOTENSION
- HEMOGLOBINURIA • BLEEDING
- RENAL FAILURE

Main symptoms of Acute hemolytic reaction



Freshly Hemolyzed Plasma (Actual Case from an OR)



Dr. DeChristopher's
gloved fingers

Febrile Nonhemolytic Transfusion Reactions


- **Cardinal Signs & Symptoms** (near end of transfusion or up to 2 hours posttransfusion)
 - **Fever**
 - **Chills / *cold feeling*** are more common than **frank *fever***
 - **General discomfort**
 - **Less commonly rigors, nausea/vomiting, dyspnea**
 - **Not associated with clinical hemolysis (by laboratory testing)**

FNTRs


- **Common Etiologies**

- Pre-formed recipient WBC antibodies
 - Chronically, heavily transfused recipients
 - Multi-gravid females
 - Solid-organ transplant recipients
- *Storage lesion* cytokines, termed a “*Cytokine Storm*”
 - Proinflammatory cytokines, such as IL-1, IL-2, IL-6, IL-8, TNF- α , in the blood components


Febrile Reactions: Rule Out Hemolysis & Acute Bacterial Sepsis



Bacterial Contamination and/or Endotoxemia



The Cavalcade of Bacterial Stars Implicated in Transfusion-transmitted Septic Deaths



Simple Cutaneous Hypersensitivity

- Usually involves the skin and is limited anatomically
- Common, but usually mild / self-limited
- More common in recipients of large volumes of **plasma**
- The transfusion can temporarily be halted
- Consider administration of antihistaminic medications
- Can restart the transfusion if non-progressive
- Not required by *AABB Standards* to be reported as a “*transfusion reaction*”

Allergic Transfusion Reactions: Hives and Itching



Acute Anaphylactic Shock

ANAPHYLACTIC REACTION

PATIENT IN
SHOCK AFTER
RECEIVING A
SMALL QUANTITY
OF BLOOD.



- Acute cardiopulmonary collapse
- Evolves **RAPIDLY**
- **Plasma proteins** are etiologic
- **Cannot be predicted or prevented**
- “Reactions” occur after exposure to only small quantities of blood
- Will likely require ACLS



Consensus Definition of TRALI

- A new ALI within **6 hours** of a completed transfusion
- No other temporally-associated ALI risk factors
- TRALI is a *clinical syndrome* rather than a disease with a single etiology
- It is a clinical and radiographic diagnosis
- TRALI is **NOT** diagnosed based on laboratory test results





Canadian Consensus Conference Panel on TRALI

- Acute onset
- Hypoxemia
 - Research setting
 - $\text{PaO}_2 / \text{FiO}_2$ ratio ≤ 300 mm Hg or
 - $\text{SpO}_2 < 90\%$ on room air
 - Non-research setting
 - As above or other clinical evidence of **hypoxemia**
- Bilateral infiltrates on frontal CXR
- No evidence of left atrial hypertension (circulatory overload)



Transfusion-Related Acute Lung Injury (TRALI)

- **Very common signs / symptoms**
 - Dyspnea, respiratory distress, hypoxia, bilateral pulmonary edema, fever (1 – 2 degree increase)
- **Common signs / symptoms**
 - Tachycardia, hypotension, cyanosis
- Diagnosis includes ruling out cardiogenic causes of pulmonary edema
- **A clinical diagnosis of exclusion**


1st Basic Mechanism Proposed for TRALI Pathogenesis

- **1st Mechanism (antibody-mediated):**
 - Specific antibodies
 - Usually HLA Class I or anti-granulocyte
 - PMN's with cognate antigens
 - Pulmonary leukostasis and PMN activation
 - (Positive complement activation)
 - **Endothelial injury, capillary leak, ALI**


2nd Basic Mechanism Proposed

- *Two-Hit*, two independent events:
 - **Systemic inflammation** (patient *primed* by underlying clinical condition)
 - Release of **proinflammatory mediators**
 - Inflammatory cytokines
 - *Storage lesion lysophosphatidylcholines* & neutral lipids
 - Pulmonary leukostasis, PMN activation and release of “reactive oxygen species”
 - **Endothelial injury, capillary leak, ALI**

The Business End of Respiration and of TRALI




Diffuse Alveolar Damage



Hyaline Membranes



Pulmonary Congestion and Edema






Transfusion Reactions with Respiratory Symptoms: **TRALI**

Risk Factors

- Higher odds among specific groups
 - Age 65 – 79 vs. older than 79 years
 - Rates higher for platelet and plasma-containing transfusions
 - Females vs. males
 - White vs. nonwhite
 - (Incidence 0.02%)
- Post-inflammatory pulmonary fibrosis
- Cancers of blood forming tissues
- Pulmonary insufficiency following trauma or surgery
- Tobacco use
- Blood transfusion



Transfusional Hypervolemia, *aka TACO*



Transfusion Reactions with Respiratory Symptoms: TACO

Risk Factors

- Patient demographics
 - Age (60% \geq 70 years of age)
 - \geq 80 years, **4-fold higher** rate (7.4% vs. 2.0%)
 - 1 : 68 – 1 : 1566 risk in **plasma recipients**
 - 1 : 356 transfused ICU patients
- Medical Conditions (critically ill vulnerable)
 - Chronic renal failure (OR **27.0**)
 - Left ventricular dysfunction (OR **8.23**)
 - Congestive heart failure (OR **6.6**)
 - Blood transfusion (OR **1.11** / unit)
- Perioperative setting (4.3% incidence)
 - Vascular, transplant & thoracic surgeries highest rates
 - Increasing transfusion volumes
 - Positive fluid balance

Transfusional Hypervolemia, *aka TACO*

- **Must Be Distinguished from TRALI**
- **TACO Kills!!**
- **Some Distinguishing Characteristics**
 - Usually affects patients at the age extremes
 - Evaluate fluid status (I's & O's)
 - Evaluate BNP
 - SOB, pulmonary congestion, distended neck veins, cyanosis, peripheral edema
- **Preventive Measures**
 - Avoid transfusions!
 - Slower transfusion rates
 - Aliquoting components
 - Concomitant diuresis / volume reduction

Comparing TRALI & TACO

	TRALI	TACO
Similar Features		
• Chest X-ray	Diffuse bilateral infiltrates	Diffuse bilateral infiltrates
• Respiratory Symptoms	Acute dyspnea	Acute dyspnea
• Auscultation	Rales	Rales

TRALI = transfusion-related acute lung injury;
TACO = transfusion-associated circulatory overload

Skeate RC, Eastlund T, Distinguishing between transfusion-related acute lung injury and transfusion-associated circulatory overload, *Curr Opin Hematol* **2007**;14: 682-87.

Comparing TRALI & TACO

	TRALI	TACO
Disparate Features		
• Temperature	Often elevated	Often unchanged
• Blood pressure	Hypotension	Hypertension
• Pulmonary artery occlusion pressure	≤ 18 mm Hg	> 18 mm Hg
• Response to diuretic	Minimal	Significant
• WBC count	May have transient leukopenia	Unchanged
• Pulmonary edema fluid	Exudate	Transudate
• Fluid balance	Positive, even, negative	Positive

- **Patients with either may lack *typical* features**
- **Patients with TRALI may have TACO features**
- **TRALI & TACO may present concurrently**

TRALI vs. TACO



TRALI

Signs & Symptoms

- Respiratory distress
- Tachypnea
- Hypoxemia
- Hypotension
- **Noncardiogenic** pulmonary edema
- Fever
- Onset within 6 hours of transfusion

Supporting Data

- B/L pulmonary infiltrates on CXR
- Decreased WBC count
- *Associated with* HLA and/or Neutrophil Antibodies

TACO

Signs & Symptoms

- Respiratory distress
- Tachypnea
- Hypoxemia
- **Hypertension**
- **Cardiogenic** pulmonary edema
- Improves with diuretics

Supporting Data

- B/L pulmonary infiltrates on CXR
- Pretransfusion **fluid overload**
- **Elevated BNP**
- Increased heart size
- Vascular congestion
- Pulmonary wedge P > 18 mm Hg





Admission Parameters

- 77-y/o female with PMH of invasive ductal breast carcinoma and SLL / CLL, both 4 years PTA
- CBC showed: H & H of 5.8 g/dL & 17.4%; WBC 119 K / μ L (98% lymphs); platelets 25 K / μ L
- The CLL was “*end-stage*”, refractory to all prior treatment attempts
- Patient refused further oncologic therapy!!
- Admitted for evaluation and treatment of cytopenias, specifically the anemia
- Plan was to provide RBC transfusion, then d/c to home or other hospice care.



Admission Parameters

- Patient had a chronic UTI x 3 months, sinus congestion and a productive cough (no evidence of pneumonia), aFib with RVR
- Transfusion support (cellular components):
 - Irradiation
 - Leukoreduction
 - CMV-seronegative
 - XM-compatible
- Three units of RBC were ordered
- The patient was pre-medicated with 375 mg of acetaminophen



Three RBC Transfusions Given over an Elapsed 10-Hour Period

#1: Begun 00:45, Completed 03:35

Vital Signs	Pre-Txn	Post-Txn
Temp (°C)	36.3	36.6
Pulse	66	80
BP	108/53	119/55
Respirations	20	20

#2: Begun 04:10, Completed 07:00

Vital Signs	Pre-Txn	Post-Txn
Temp (°C)	36.6	36.5
Pulse	70	64
BP	108/54	144/80
Respirations	20	20

#3: Begun 08:00, Completed 10:00

Vital Signs	Pre-Txn	Post-Txn
Temp (°C)	36.5	36.9
Pulse	64	87
BP	144/80	196/84
Respirations	20	20





Unintended Consequences

- 12:00: Anxiety & agitation set in, but breathing normal
- 14:00: Dyspnea & increased WOB began
- 18:00: Cough developed with frothy, bloody sputum, AMS, lethargy, a/w desaturations → intubated & MICU transfer
- New-onset symptoms, associated abnormalities:
 - **Positive** fluid balance - Net I's / O's + **2600 mL**
 - CXR with cardiomegaly new B/L lower lobe opacities
 - EKG with atrial flutter & new RBBB
 - Troponin I level at **0.69 ng/mL**
 - **BNP 743 pg/mL**
- Worsening, refractory hypotension. DNR status & comfort care elected. Patient expired 12 hours posttransfusion.



And Your Diagnosis Is?

- Narrow Differential
 - **TACO vs. TRALI**
- Reportabilities?
 - To whom would YOU report this event?
 - The Blood Bank, order a “*Transfusion Reaction Work-up*”
 - Your immediate superiors
- To whom is such events required to be reported?
 - Institutional Patient Safety / Risk Management
 - Regional Blood Center (why?)
 - The FDA!!
- One of 3 RBC donors was a female with broad HLA alloimmunization!! (Possible TRALI!)

What's Being Done to Mitigate Risks of Transfusion?

- Blood Center Donor Qualification, Unit Disease and other Testing:
 - ABO, Rh, antibody screen
 - Serologic tests
 - Syphilis (RPR or VDRL)
 - HBsAg, anti-HBc and anti-HCV
 - Retroviruses: Anti-HIV-1/2, anti-HTLV-I/II
 - Anti-*trypanosoma cruzi* (Chagas' disease)
 - Genomic amplification methods
 - HIV-1
 - HCV
 - HBV
 - WNV
 - Zika virus



TRALI Mitigation Strategies

- **Provision & transfusion of “*all-male*” plasma**
 - Successful in Europe since 2003
 - Difficult to meet AB plasma demands from *male-only donors*
 - The US incidence of FDA-reported TRALI deaths from plasma has significantly decreased since FY07
 - TRALI deaths still occur with RBC transfusion
- Qualify female platelet donors by testing for HLA and neutrophil antibodies



Other Risk Mitigation Strategies

- “Universal” leukoreduction
 - Reduces FNHTRs
 - Reduces alloimmunization to HLA antigens
 - Reduces platelet refractoriness
 - Reduces risk of CMV transmission
 - Reduces mediastinitis in CT surgery
- “All male” plasma selection (reduces TRALI risks)
- HLA / neutrophil Ab screening, female platelet donors
- Supplemental bacteriologic testing of platelets
- Repeat ABO / Rh testing to confirm recipient typing
- Selective recipients protections (e.g. CMV, irradiation)
- Application of pathogen inactivation techniques / products

What are YOU Prepared to Do to Mitigate Risks of Transfusion?



- Employ robust specimen & patient identification know-how
- Discover the literature: IDENTIFY the evolving evidence base & indications for transfusion therapy!
- Informed consent for transfusion: Describe & weigh risks!
- Limit or avoid transfusion (one element of *Patient Blood Management*)
 - **Don't order 2 when 1 will do!**
- Learn how to appropriately order blood in Epic
- Recognize requirements for surgical blood ordering
- **Report *suspected* Transfusion Reactions to Blood Bank**
- Identify & use our institutional urgent agent reversal strategies in life-threatening bleeding
- *The Pharmacy is your friend!* (Alternatives to transfusion)



8 Rights of Transfusion Administration

8 RIGHTS:

- Product
- Patient
- Dose
- Time
- Reason
- Site
- Documentation
- Response



Transfusion Complications that Kill

- Acute intravascular hemolysis
- **TACO**
- **TRALI**
- Bacterial contamination
- Other microorganism contamination
- Anaphylaxis
- (Hyperhemolytic syndrome)
- Complications of Immunomodulation
- Acute TR graft-vs-host disease

The Risk Side of the Transfusion Equation

- Blood transfusion is a “*liquid transplant*”
- Blood transfusion risks can be mitigated, but not eliminated (“*unavoidably unsafe*”)
- There is always another “*microorganism of the month*” waiting in the wings
- Blood transfusions are the only tissues casually transplanted with the stroke of a *mouse* click
- **The safest transfusion is the one you don’t give**